Prediction of pathological complete response and prognosis in patients with neoadjuvant treatment for triple-negative breast cancer

被引:60
|
作者
Gass, Paul [1 ]
Lux, Michael P. [1 ]
Rauh, Claudia [1 ]
Hein, Alexander [1 ]
Bani, Mayada R. [1 ]
Fiessler, Cornelia [2 ]
Hartmann, Arndt [3 ]
Haeberle, Lothar [1 ,4 ]
Pretscher, Jutta [1 ]
Erber, Ramona [3 ]
Wachter, David L. [3 ]
Schulz-Wendtland, Ruediger [5 ]
Beckmann, Matthias W. [1 ]
Fasching, Peter A. [1 ]
Wunderle, Marius [1 ]
机构
[1] Friedrich Alexander Univ Erlangen Nuremberg, Erlangen Univ Hosp, Univ Breast Ctr Franconia, Dept Gynecol & Obstet,Comprehens Canc Ctr Erlange, Univ Str 21-23, D-91054 Erlangen, Germany
[2] Friedrich Alexander Univ Erlangen Nuremberg, Dept Med Informat Biometry & Epidemiol, Waldstr 6, D-91054 Erlangen, Germany
[3] Friedrich Alexander Univ Erlangen Nuremberg, Erlangen Univ Hosp, Inst Pathol, Krankenhausstr8-10, D-91054 Erlangen, Germany
[4] Erlangen Univ Hosp, Biostat Unit, Dept Gynecol & Obstet, Univ Str 21-23, D-91054 Erlangen, Germany
[5] Friedrich Alexander Univ Erlangen Nuremberg, Erlangen Univ Hosp, Inst Diagnost Radiol, Maximilianspl 3, D-91054 Erlangen, Germany
关键词
Triple-negative breast cancer; Neoadjuvant therapy; Platinum; Pathological complete response; Prognosis; Prediction; HOMOLOGOUS RECOMBINATION DEFICIENCY; DNA-REPAIR; CHEMOTHERAPY; BRCA1; MUTATION; CARBOPLATIN; SURVIVAL; THERAPY; RATES; CARE;
D O I
10.1186/s12885-018-4925-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundIt has been reported that pathological complete response is an important surrogate marker for disease-free survival and overall survival in patients with triple-negative breast cancer. This study investigates predictors of the response to neoadjuvant platinum-based or anthracycline-based treatment, and of the prognosis, in patients with triple-negative breast cancer.MethodsA total of 121 patients with triple-negative breast cancer received neoadjuvant treatment with either platinum or anthracycline between 2008 and 2013. Pathological complete response was assessed relative to different treatments using logistic regression models with age, clinical tumor stage, grading, and Ki-67 as predictors and interaction terms, to obtain adjusted and subgroup-specific results. The impact of the pathological complete response rate on disease-free survival and overall survival was also analyzed.ResultsThe pathological complete response rate was higher after platinum/taxane treatment compared with anthracycline/taxane (50.0% vs. 41.8%), but this was not significant in the adjusted analysis (OR 1.44; 95% CI, 0.68 to 3.09). A high histological grade (G3) was a predictor for higher pathological complete response in platinum-based therapy (OR 2.27; 95% CI, 1.00 to 5.30). The effect of neoadjuvant chemotherapy on pathological complete response was significantly different for G1-2 vs. G3 (P-interaction=0.013), and additional subgroup-specific differences were noted. Pathological complete response was a predictor for improved disease-free survival and overall survival in both treatment groups, with and without platinum chemotherapy.ConclusionsThis retrospective study of patients with triple-negative breast cancer adds to the evidence that the treatment effect of platinum may be greatest particularly in G3 tumors. In addition, the effect of pathological complete response on the prognosis does not depend on the treatment used.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] Prediction of pathological complete response and prognosis in patients with neoadjuvant treatment for triple-negative breast cancer
    Paul Gass
    Michael P. Lux
    Claudia Rauh
    Alexander Hein
    Mayada R. Bani
    Cornelia Fiessler
    Arndt Hartmann
    Lothar Häberle
    Jutta Pretscher
    Ramona Erber
    David L. Wachter
    Rüdiger Schulz-Wendtland
    Matthias W. Beckmann
    Peter A. Fasching
    Marius Wunderle
    BMC Cancer, 18
  • [2] Novel biomarkers and prediction model for the pathological complete response to neoadjuvant treatment of triple-negative breast cancer
    Han, Yiqun
    Wang, Jiayu
    Xu, Binghe
    JOURNAL OF CANCER, 2021, 12 (03): : 936 - 945
  • [3] Clinical predictors of pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer
    Nakashoji, Ayako
    Matsui, Akira
    Nagayama, Aiko
    Iwata, Yuko
    Sasahara, Manami
    Murata, Yuya
    ONCOLOGY LETTERS, 2017, 14 (04) : 4135 - 4141
  • [5] Collagen Density Is Associated With Pathological Complete Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Patients
    Li, Fengling
    Wei, Yani
    Li, Li
    Chen, Fei
    Bao, Chunjuan
    Bu, Hong
    Zhang, Zhang
    JOURNAL OF SURGICAL ONCOLOGY, 2024,
  • [6] The response to neoadjuvant chemotherapy and prognosis of triple-negative breast cancer patients.
    Nakano, E.
    Hojo, T.
    Masumura, K.
    Kikuyama, M.
    Akashi, S.
    Kinoshita, T.
    CANCER RESEARCH, 2009, 69 (02) : 337S - 337S
  • [7] A preliminary study on predicting pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer
    Chen, Xi
    Zhou, Zhiguo
    CANCER RESEARCH, 2024, 84 (03)
  • [8] Multimodal machine learning model prediction of complete pathological response to neoadjuvant chemotherapy in triple-negative breast cancer.
    Groheux, David
    Ferrer, Loic
    Vargas, Jennifer
    Martineau, Antoine
    Teixeira, Luis
    Menu, Philippe
    Bertheau, Philippe
    Gallinato, Olivier
    Colin, Thierry
    Lehmann-Che, Jacqueline
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [9] Response and prognosis of taxanes and anthracyclines neoadjuvant chemotherapy in patients with triple-negative breast cancer
    Wu, Jiannan
    Li, Shunrong
    Jia, Weijuan
    Su, Fengxi
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2011, 137 (10) : 1505 - 1510
  • [10] Response and prognosis of taxanes and anthracyclines neoadjuvant chemotherapy in patients with triple-negative breast cancer
    Jiannan Wu
    Shunrong Li
    Weijuan Jia
    Fengxi Su
    Journal of Cancer Research and Clinical Oncology, 2011, 137 : 1505 - 1510